IGKV6D-21 and glioblastoma: To investigate integrin α10β1 as a potential drug target in GBM, we constructed an ADC that combines a monoclonal integrin α10 mouse antibody with the ribosome-inactivating cytotoxin saporin (anti-α10-SAP).